Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576779 · ClinicalTrials.gov registry record
Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,101
- Enrollment target
NCT05576779: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05576779 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05576779 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,101 participants
- Enrollment target
Study Summary
This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
Primary Outcome
The primary measure was pre-index treatment status of patients initiating ofatumumab, measured as proportion (n, %) of DMT-naïve and DMT-experienced patients among patients initiating ofatumumab based on DMT use in the 12-month pre-index period.
Interventions
- OTHER Ofatunumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,101 participants |
| Start Date | 2020-12-03 |
| Est. Completion | 2021-12-31 |
What the finished NCT05576779 record still lists
NCT05576779 is an observational study that tracks outcomes without assigning an intervention. Its 2,101 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Ofatunumab is the first listed.
NCT05576779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05576779 about?
NCT05576779 is a clinical study titled "Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.". This was a retrospective cohort study utilizing secondary data from IQVIA's open source pharmacy claims database (i.e., IQVIA LRx) selecting patients with prescription claims for ofatumumab or other DMTs of interest.
What is the current status of trial NCT05576779?
This trial is currently completed. The enrollment target is 2,101 participants. The study started on 2020-12-03. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT05576779?
The interventions under investigation include: Ofatunumab (OTHER).
Who is sponsoring clinical trial NCT05576779?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI